Aging in later life is often portrayed as a steady slide toward physical and cognitive decline. But a new study by scientists at Yale University suggests an alternate narrative — that older individuals can and do improve over time and their mindset toward aging plays a major part in their success.

Analyzing more than a decade of data from a large, nationally representative study of older Americans, lead author Becca R. Levy, a professor of social and behavioral sciences at the Yale School of Public Health (YSPH), found that nearly half of adults aged 65 and older showed measurable improvement in cognitive function, physical function, or both, over time.

The improvements were not limited to a small group of exceptional individuals and, notably, were linked to a powerful but often overlooked factor: how people think about aging itself.

“Many people equate aging with an inevitable and continuous loss of physical and cognitive abilities,” said Levy, an international expert on psychosocial determinants of aging health. “What we found is that improvement in later life is not rare, it’s common, and it should be included in our understanding of the aging process.”

The findings are published in the journal Geriatrics.

A new international study published in The Lancet eClinicalMedicine has mapped global blood transfusion practices for life-threatening abdominal injuries, highlighting significant variation in care worldwide and opportunities for health systems to learn from one another.

Groundbreaking Phase 1/2a clinical trials co-led by Linda Laux, MD, from Ann & Robert H. Lurie Children’s Hospital of Chicago, show that the first gene regulation treatment for epilepsy is safe and well tolerated by patients with Dravet syndrome for whom antiseizure medications are not effective. Results, published in the New England Journal of Medicine, include significant seizure reduction and improvement in other symptoms of Dravet syndrome, such as language, motor and behavior issues. Researchers also report sustained treatment benefits in ongoing open-label extension studies.